SynthesisIntensive care medicine2019
Safety and efficacy of erythropoiesis-stimulating agents in critically ill patients admitted to the intensive care unit: a systematic review and meta-analysis.
Synthesis in Intensive care medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 3 syntheses or guidelines pooled it, 51 citations in OpenAlex.
- Effects of growth hormone and anabolic steroids, in critically ill patients admitted to the intensive care unit: a systematic review and meta-analysis.Scientific reports · 2025Pooled it
- Erythropoiesis-stimulating agents for preventing acute kidney injury.The Cochrane database of systematic reviews · 2024Pooled it
- Adverse events of iron and/or erythropoiesis-stimulating agent therapy in preoperatively anemic elective surgery patients: a systematic review.Systematic reviews · 2022Pooled it
- Patient blood management in general intensive care patients.Intensive care medicine · 2026Review
- Anemia of Critical Illness: A Concise Definitive Review in Critical Care.Critical care medicine · 2026Review
- Association between red blood cell transfusion and adverse clinical outcomes is Independent of cardiac history: a multicenter observational InPUT study analysis.Critical care (London, England) · 2025Observational
- Management of anaemia in critically ill adults.Singapore medical journal · 2025Article
- Erythropoietin for Seizures and Epilepsy: Neuroprotective Effects, Mechanisms, and Contradictory Risks.CNS & neurological disorders drug targets · 2025Review
- Managing preoperative anemia: EPO is needed.Blood transfusion = Trasfusione del sangue · 2025Article
- Effect of erythropoietin on SOFA score, Glasgow Coma Scale and mortality in traumatic brain injury patients: a randomized-double-blind controlled trial.Annals of medicine and surgery (2012) · 2024Article
- Impact of anemia requiring transfusion or erythropoiesis-stimulating agents on new-onset cardiovascular events and mortality after continuous renal replacement therapy.Scientific reports · 2024Article
- Iron and erythropoietin to heal and recover after intensive care (ITHRIVE): A pilot randomised clinical trial.Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine · 2023Article
- Effect of Deferoxamine on Post-Transfusion Iron, Inflammation, and In Vitro Microbial Growth in a Canine Hemorrhagic Shock Model: A Randomized Controlled Blinded Pilot Study.Veterinary sciences · 2023Article
- Practical Anemia Bundle for Sustained Blood Recovery (PABST-BR) in critical illness: a protocol for a randomised controlled trial.BMJ open · 2022Article
- Early Post-Hospitalization Hemoglobin Recovery and Clinical Outcomes in Survivors of Critical Illness: A Population-Based Cohort Study.Journal of intensive care medicine · 2022Observational
- Patient blood management in the ICU: A narrative review of the literature.European journal of anaesthesiology and intensive care · 2022Review
- Age and genotype dependent erythropoietin protection in COVID-19.World journal of stem cells · 2021Review
- Addressing the 'hypoxia paradox' in severe COVID-19: literature review and report of four cases treated with erythropoietin analogues.Molecular medicine (Cambridge, Mass.) · 2021Review
- Coronavirus Disease 2019 (COVID-19): A Haematologist's Perspective.Acta haematologica · 2021Review
- Treating critically ill anaemic patients with erythropoietin: why not?Intensive care medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeSevere immune dysregulation is common in patients admitted to the intensive care unit (ICU) and is associated with adverse outcomes. Erythropoietin-stimulating agents (ESAs) have immune-modulating and anti-apoptotic effects. However, their safety and efficacy in critically ill patients remain uncertain. We evaluated whether ESAs, administered to critically unwell adult patients admitted to the ICU, reduced mortality at hospital discharge.
methodsThe search strategy was conducted according to a predetermined protocol and included OVID MEDLINE, OVID EMBASE and The Cochrane Central Register of Controlled Trials from inception until 20 May 2019. Publications were eligible for inclusion if they were randomized controlled trials (RCTs) including adult patients admitted to an ICU, that identified and reported a group receiving ESA therapy compared to a group not receiving ESA therapy and reported mortality. There were no language restrictions.
resultsThe systematic review included 21 studies with 5452 participants. In-hospital mortality, reported in 16 studies of which only one was at low risk of bias, was lower in the ESA group (276 of 2187 patients, 12.6%) than the comparator group (339 out of 2204 patients, 15.4%), [relative risk (RR) 0.82, 95% CI 0.71-0.94, P = 0.006, I
conclusionsIn heterogenous populations of critically ill adults, evidence from RCTs of mainly low or unclear quality, suggests that ESA therapy may decrease mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.